RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

The rest of the world is not "full of fools"--and I don't think I implied that. When the limited subset of investors and institutions, for whom small niche companies like Cortex are even on the radar, see Cortex's own banker call for a firesale of the company, while predicting a target price of cash value a year from now--that carries a lot of weight. There aren't many people who pay enough attention to the situation that they can see that there is an agenda at work here that has nothing to do with accuracy--or honesty, for that matter. And I am not talking about the public at large, or about Cortex itself. What we are seeing are failures within two institutions: the FDA and Rodman & Renshaw: they have failed to do their jobs competently and honorably.

That is, of course, just my opinion. And both institutions will have the opportunity to rectify their failures. Whether or not either will take it, I don't know. But the form of contrition I expect is this: 1) the Psychiatry division will eventually get CX701 submitted to them by Cortex or a partner--and they will allow the IND. To show that they are, after all, fair people. And when the RD trial produces proof of concept next spring, and Schering-Plough makes some noise about their Ampakine programs--Rodman and Renshaw, having failed to compel the firesale, will grudgingly issue a note acknowledging that Cortex's prospects have improved, and along with them, the target price.

NeuroInvestment